PROSPECTIVE ASSESSMENT OF THE FOLLICULAR GROWTH AND THE OOCYTE COHORT AFTER CONTROLLED OVARIAN HYPERSTIMULATION (COH) FOR FERTILITY PRESERVATION IN 90 YOUNG CANCER PATIENTS VERSUS 180 MATCHED CONTROLS

Keller, Laura1; Robin, Geoffroy2; Mailleix, Audrey3,1; Ramdane, Nassima4; Morschhauser, Franck5; Leroy-Martin, Brigitte1; Decanter, Christine6

1Institut de Biologie de la Reproduction-Spermiologie-CECOS, hôpital jeanne de Flandre, Centre Hospitalier Universitaire de Lille, Lille, France., 2Centre d’Assistance médicale à la Procréation et de Préservation de la Fertilité, Hôpital Jeanne de Flandre, Centre Hospitalier Universitaire de Lille, Lille, France., 3Centre anti-cancéreux Oscar Lambret, Département de Sénologie, Lille, France, 4Centre d’études et de recherche en Informatique Médicale, Centre Hospitalier Universitaire de Lille, Lille, France., 5Service des maladies du Sang, Hôpital Huriez, Centre Hospitalier Universitaire de Lille, France, 6à Centre d’Assistance médicale à la Procréation et de Préservation de la Fertilité, Hôpital Jeanne de Flandre, Centre Hospitalier Universitaire de Lille, Lille, France.

Abstract Body

INTRODUCTION : Recent retrospective studies highlighted a lower number of metaphase II oocytes eligible for vitrification after COH in cancer patients suggesting that the disease may impair the dynamics and the quality of follicular growth.

OBJECTIVE : The current study is a prospective comparative study analysing the pattern of follicular growth and oocyte cohort after COH in cancer patients.

MATERIALS AND METHODS : 90 cancer patients, recruited before starting chemotherapy, were compared to 180 time and age-matched healthy ICSI controls underwent their first attempt and all patients received an antagonist protocol. Primary outcome of the study was the total number of metaphase II oocytes and the metaphase II /total oocytes rate.

RESULTS : The distribution of the different types of cancer was as follows: 54% of breast cancer, 28% of haematological malignancies and 18% of various solid tumors. Patients did not differ from controls regarding age and BMI. Basal AMH levels and AFC were significantly lower in cancer patients. The r-FSH total dose was significantly higher in the cancer group. The duration of stimulation, the mean number of mature follicles on triggering day and the total oocyte number after retrieval were not different between the two groups. The mean number of Metaphase II oocytes and Metaphase II / total oocytes ratio were significantly lower in the cancer group (6.3 ± 4.7 vs 8.8 ± 4.2; p ≤ 0.0001 and ) were significantly lower in the cancer group (56% vs 78% p ≤ 0.0001) with a higher rate of atretic oocytes.

CONCLUSION : Our results confirm those of the largest previous retrospective reports, with a lower number of metaphase II oocytes eligible for vitrification and lower maturation rate in the cancer group.